[{"id":"b84fa649-6a21-4a69-88fb-39a7bfebf3aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02422641","created_at":"2021-01-18T11:35:12.764Z","updated_at":"2024-07-02T16:35:19.750Z","phase":"Phase 2","brief_title":"Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis","source_id_and_acronym":"NCT02422641","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-12"},{"id":"ae4f0bcf-92e9-4aec-bed9-90d3c7787dc5","acronym":"BRE-08","url":"https://clinicaltrials.gov/study/NCT06085742","created_at":"2023-10-17T15:12:33.591Z","updated_at":"2024-07-02T16:35:23.572Z","phase":"Phase 2","brief_title":"BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer","source_id_and_acronym":"NCT06085742 - BRE-08","lead_sponsor":"University of Illinois at Chicago","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • methotrexate"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2023","start_date":" 11/22/2023","primary_txt":" Primary completion: 09/01/2034","primary_completion_date":" 09/01/2034","study_txt":" Completion: 09/01/2034","study_completion_date":" 09/01/2034","last_update_posted":"2024-01-12"},{"id":"01d7872c-62e6-480f-8138-2caec3d153a4","acronym":"METHOGLU","url":"https://clinicaltrials.gov/study/NCT05135858","created_at":"2021-11-26T14:53:40.439Z","updated_at":"2024-07-02T16:36:01.882Z","phase":"Phase 1","brief_title":"Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma","source_id_and_acronym":"NCT05135858 - METHOGLU","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" IL10","pipe":"","alterations":" ","tags":["IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2022-10-25"},{"id":"35e30234-162e-4d4d-9d1e-a643e2c4f332","acronym":"","url":"https://clinicaltrials.gov/study/NCT05522582","created_at":"2022-08-31T16:59:08.947Z","updated_at":"2024-07-02T16:36:02.903Z","phase":"Phase 2","brief_title":"Methotrexate Combined With Immunotherapy During Radiotherapy for Solid Tumors","source_id_and_acronym":"NCT05522582","lead_sponsor":"Yancheng First People's Hospital","biomarkers":" CD8 • IL6 • CD4","pipe":"","alterations":" ","tags":["CD8 • IL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/15/2021","start_date":" 11/15/2021","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-10-06"},{"id":"e0760145-1870-4eb2-bfda-4eec6ab03abe","acronym":"NCI-2018-02609","url":"https://clinicaltrials.gov/study/NCT03518242","created_at":"2021-01-18T17:19:06.525Z","updated_at":"2025-02-25T13:18:30.911Z","phase":"Phase 1","brief_title":"Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer","source_id_and_acronym":"NCT03518242 - NCI-2018-02609","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • cyclophosphamide • methotrexate • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 05/04/2022","primary_completion_date":" 05/04/2022","study_txt":" Completion: 05/04/2022","study_completion_date":" 05/04/2022","last_update_posted":"2022-06-08"},{"id":"63d27786-955f-456f-9b97-5a7e4032fa84","acronym":"","url":"https://clinicaltrials.gov/study/NCT00267865","created_at":"2021-01-18T00:54:41.110Z","updated_at":"2024-07-02T16:36:44.616Z","phase":"Phase 2","brief_title":"Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma","source_id_and_acronym":"NCT00267865","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • methotrexate • leucovorin calcium • Xatmep (methotrexate oral solution) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 09/14/2006","start_date":" 09/14/2006","primary_txt":" Primary completion: 09/18/2019","primary_completion_date":" 09/18/2019","study_txt":" Completion: 09/19/2019","study_completion_date":" 09/19/2019","last_update_posted":"2020-06-01"},{"id":"407ac7e6-0c0a-45e1-bb71-0bd4c56bdc2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01848457","created_at":"2021-01-18T08:14:55.358Z","updated_at":"2024-07-02T16:36:48.338Z","phase":"Phase 2","brief_title":"Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","source_id_and_acronym":"NCT01848457","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" KIM1","pipe":"","alterations":" ","tags":["KIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xatmep (methotrexate oral solution) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 01/04/2016","primary_completion_date":" 01/04/2016","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2020-03-16"},{"id":"8bd18935-92e1-413b-9e77-12c5e21553f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04283955","created_at":"2021-01-18T20:47:49.261Z","updated_at":"2024-07-02T16:36:49.619Z","phase":"","brief_title":"A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04283955","lead_sponsor":"Sun Yat-sen University","biomarkers":" MTHFR","pipe":" | ","alterations":" MTHFR C677T","tags":["MTHFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTHFR C677T"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-02-25"},{"id":"2c963528-7afd-4228-bbe1-de43b927ac81","acronym":"","url":"https://clinicaltrials.gov/study/NCT00083031","created_at":"2021-01-18T00:14:08.035Z","updated_at":"2024-07-02T16:36:59.407Z","phase":"Phase 2","brief_title":"Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT00083031","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • ER positive + PGR positive • PGR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cyclophosphamide • methotrexate • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 07/01/2003","start_date":" 07/01/2003","primary_txt":" Primary completion: 08/01/2006","primary_completion_date":" 08/01/2006","study_txt":" Completion: 08/01/2009","study_completion_date":" 08/01/2009","last_update_posted":"2019-05-21"},{"id":"9b1c416a-22dc-4c2b-8766-a5856dc1dd31","acronym":"","url":"https://clinicaltrials.gov/study/NCT02724904","created_at":"2021-01-18T13:20:13.317Z","updated_at":"2024-07-02T16:37:24.188Z","phase":"Phase 1/2","brief_title":"Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma","source_id_and_acronym":"NCT02724904","lead_sponsor":"Massachusetts General Hospital","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • thiotepa"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2017-03-22"}]